ReviewCurrent diabetes reports2010
Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors.
Review in Current diabetes reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 27 citations in OpenAlex.
- Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.Clinical drug investigation · 2011Trial
- Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus.North American journal of medical sciences · 2014Review
- The Sweet Pee model for Sglt2 mutation.Journal of the American Society of Nephrology : JASN · 2011Article
- Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin.Pakistan journal of medical sciencesArticle
- Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.Indian journal of endocrinology and metabolismReview
- Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.Indian journal of endocrinology and metabolismReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperglycemia is important in the development of microvascular and macrovascular complications from type 2 diabetes. Although there are many oral therapies available to help ameliorate hyperglycemia, it has been found that the competitive inhibition of the sodium-D-glucose cotransporter-2 (SGLT2) in the kidney may be a promising alternative treatment reducing hyperglycemia and potentially helping to lower the risk of diabetes complications. This article reviews clinical trials that have revealed favorable responses to many glycemic and metabolic parameters with SGLT2 inhibition, both as monotherapy and as an adjunct to insulin and oral antidiabetic agents. Additional studies are necessary to further determine the efficacy and long-term safety of SGLT2 inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.